Fly News Breaks for December 2, 2019
Dec 2, 2019 | 09:25 EDT
Piper Jaffray analyst Matt O'Brien believes Baxter International's acquisition of the Seprafilm Adhesion Barrier product and related assets from Sanofi (SNY) is a "solid addition" at "reasonable price." Shares of Baxter have recovered a bit from the Q3 financial misstatement disclosure but still have much farther to go and today's deal "should assist in the recovery," O'Brien tells investors in a research note. He keeps an Overweight rating on the shares with a $95 price target.
News For BAX From the Last 2 Days
There are no results for your query BAX